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11312 | RSC Adv., 2019, 9, 11312–11321rystals as a nanoantibiotic and
osteoinductive agent†
Nadia Garino, ‡ab Pasquale Sanvitale,‡a Bianca Dumontel,a Marco Laurenti,a
Montserrat Colilla, cd Isabel Izquierdo-Barba, cd Valentina Cauda *a
and Maria Vallet-Reg`ı *cd
In this paper we aim to analyse the behaviour of ZnO nanocrystals (ZnO NCs), prepared with a new synthetic
approach and not embedded in any composite matrix, for bone implant applications in vitro. In particular, we
have developed a novel, fast and reproducible microwave-assisted synthesis, to obtain highly-crystalline,
round-shaped ZnO NCs of 20 nm in diameter as an extremely-stable colloidal solution in ethanol. The
nanocrystals were also partially chemically functionalized by anchoring amino-propyl groups to the ZnO
surface (ZnO–NH2 NCs). Thus, the role of both ZnO NC concentration and surface chemistry were tested
in terms of biocompatibility towards pre-osteoblast cells, promotion of cell proliferation and differentiation,
and also in terms of antimicrobial activity against Gram positive and negative bacteria, such as Escherichia
coli and Staphylococcus aureus, respectively. The results suggest that ZnO–NH2 NCs is the most promising
candidate to solve infectious disease in bone implants and at the same time promote bone tissue
proliferation, even at high concentrations. Although further investigations are needed to clarify the
mechanism underlying the inhibition of biofilm formation and to investigate the role of the ZnO–NH2 NCs
in in vivo assays, we demonstrated that fine and reproducible control over the chemical and structural
parameters in ZnO nanomaterials can open up new horizons in the use of functionalized ZnO NCs as
a highly biocompatible and osteoinductive nanoantibiotic agent for bone tissue engineering.Introduction
Nowadays, infections due to both Gram positive and negative
pathogens are developing an evolved resistance to conventional
antibiotics, impairing the effects of these drugs and posing
serious problems to public health in the long term. Bone infec-
tions related to the implantation of orthopaedic implants are also
facing this important antibiotic resistance issue. In particular,
during the insertion of orthopaedic implants, bacteria from
patient's skin ormucosa can enter and adhere to the surface of the
implant and start to produce an antibiotic-resistant biolm. This
phenomenon results in osteomyelitis, localised bone destruction,ology, Politecnico di Torino, Corso Duca
: valentina.cauda@polito.it
r Sustainable Future Technologies, Via
mace´uticas, Universidad Complutense de
adrid, Spain. E-mail: vallet@ucm.es
eering, Biomaterials and Nanomedicine
ESI) available: ZnO NC size distribution
-transform infrared (FT-IR) spectra,
es, cell differentiation assays in term
logy evaluation by optical microscopy.prolonged hospitalisation, intense antibiotic treatment and, in
the most serious cases, the replacement of the prosthesis.1
It is thus necessary to start exploring either new antibiotic
formulations or novel inhibition pathways to solve bacterial
resistance. Unfortunately, there is no certainty about the effec-
tiveness of new antimicrobial drugs because bacteria can
develop resistance in a timely manner. A new approach to
overcome this challenging and infectious disease can be the use
of antimicrobial nanomaterials. At rst, nanomaterials were
proposed as carriers for antibiotics to improve their pharma-
cokinetics and accumulation, and to reduce side effects.2,3 A
more innovative approach is the use of intrinsically-
antimicrobial nanomaterials, where the antimicrobial activity
is not as a result of the pharmaceutical effect of an antibiotic,
but instead comes directly from the intrinsic properties of the
nanosized material.4 To this end, several metal and metal oxide
micro- and nano-structures have been proposed due to their
ability to produce reactive oxygen species or dissolve in cations,
both toxic for the majority of microbial cells.5
Among them, zinc oxide (ZnO) is one of the most promising
inorganic antimicrobial materials. At the bulk or micro-sized
level, it shows reduced toxicity to eukaryotic cells (it is actually
considered a GRAS—generally recognized as safe—substance
approved by the US Food and Drug Administration (FDA)6) and
can overcome bacterial resistance to a certain extent.5,7This journal is © The Royal Society of Chemistry 2019
Paper RSC AdvancesThe use of nanosized ZnO in biomedical applications,8,9 in
particular in bone tissue engineering, can be envisioned owing
to its excellent antimicrobial properties, its biocompatibility
and partial biodegradability,10 facile synthetic approaches can
be used to produce materials with different sizes and shapes,11
and easily functionalizable surface.12 However, some issues are
still unsolved concerning its potential toxicity to eukaryotic
cells, which can impair either healthy or tumor cells at different
dosages.13,14 Thus, the use of ZnO as a nanoantibiotic4 requires
a careful evaluation of the interactions between the nano-
materials and living cells, tissues and adjacent organs, and thus
of dose administration and recalibration in the desired anti-
microbial therapy.
The antibacterial activity of ZnO nanostructures is related to
three main probable mechanisms:9 (i) reactive oxygen species
(ROS) generation, (ii) release of Zn2+ cations and (iii) nano-
particle action. ROS generation is the predominant mechanism
and is promoted by the presence of crystalline defects in nano-
sized ZnO structures, even in the absence of any photoactivation
stimulus. Due to the semiconductor band structure of ZnO, the
electrons (e) are promoted in the conduction band, whereas
unpaired holes (h+) remain in the valence bands. The migration
of both e and h+ at the surface of the nanomaterials promotes
their combination with water-adsorbed molecules, generating
ROS, such as hydroxyl radicals, singlet oxygen and superoxide
radicals. Hydroxyl radicals are the most reactive species and
they can quickly interact with every type of biological molecules.
The release of Zn2+ ions from ZnO nanostructures, owing to
their chemical instability in biological media,10 is another
important mechanism in the antibacterial activity of ZnO. Zn2+
ions can adsorb to the negatively charged bacteria surface
through electrostatic forces. This interaction leads to the loss of
the charge balance and deformations of the cell occur with
consequent bacteriolysis. At the same time, Zn2+ can penetrate
the cell membrane and interact with functional groups as
sulphate and phosphate groups, resulting in the structural
change of proteins, provoking the destruction of bacteria by
unbalanced metabolism.
Finally, the penetration of ZnO nanoparticles through the
bacterial membrane and its consequent disorganisation also
leads to bacterial death and thus, this is the third mechanism to
take into account. This phenomenon is specically due to the
high specic area and surface energy of ZnO nanomaterials,
which are able to adsorb and accumulate at the membrane and
in the cytoplasm.
Despite these most probable mechanisms against bacteria,
the inuence of the medium components, and the different
sizes and surface chemistry of ZnO nanomaterials also have to
be taken into account. Therefore, the real antimicrobial mech-
anisms are still under investigation and have to be proven
depending on the ZnO morphology, chemical reactivity and
surface, and also the bacteria cell type.15
It is thus crucial to control the ZnO particles' size,
morphology and surface chemistry to efficiently tune on the one
hand the antibacterial properties and on the other hand the
biocompatibility towards healthy cells in case of biomedical
implants or drug delivery devices.16This journal is © The Royal Society of Chemistry 2019Regarding the specic use of ZnO nanomaterials for bone
tissue engineering, ZnO was proposed as a suitable ller in
composite matrices based on hydroxyapatite,17,18 graphene
oxide,19 polymers,20,21 or as a coating for orthopaedic and dental
implants, promoting antibacterial response together with
osteoblast growth, adhesion and their metabolic activity.22
Colon et al.23 have analysed the effects of ZnO micro- and
nano-powders, pressed into compacts, on osteoblast functions
and S. epidermidis adhesion. The results of this study provided
the rst evidence of signicantly greater osteoblast adhesion,
alkaline phosphatase (ALP) activity, and calcium mineral
deposition on nanophase ZnO with respect to the microphase
counterpart, as well as a reduction in S. epidermidis adhesion.
Moreover, it was reported that an appropriate concentration of
zinc ions can enhance osteoblast cell proliferation and differ-
entiation,24 promoting ALP activity and osteocalcin (OCN)
secretion, considered as early and major markers of late stage
osteoblast differentiation, respectively.25
The aim of this study is to analyse the behaviour of ZnO
nanocrystals (ZnO NCs), not embedded in any composite
matrix, for bone implants applications in vitro. We have devel-
oped a novel microwave-assisted synthesis to obtain ZnO NCs in
a fast, highly-reproducible and efficient way. Such NCs, 20 nm
in diameter and with a high degree of crystallinity, can also be
chemically functionalized with amine groups, in order to
investigate in vitro the effects of their surface chemistry and
charge.
Thus, the role of ZnO NC concentration and functionaliza-
tion was tested both in terms of biocompatibility related to pre-
osteoblast cells, promotion of cell proliferation and differenti-
ation, and also in terms of antimicrobial activity against Gram
positive and negative bacteria, such as Escherichia coli and
Staphylococcus aureus. The results show the promising behav-
iour of amine-functionalized ZnO NCs for bone tissue engi-
neering, even at high concentrations, leading to promoted
osteogenic behaviour and high antimicrobial activity. It is thus
demonstrated that ne control over the chemical and structural
parameters in ZnO nanomaterials can open up new horizons in
the use of functionalized ZnO NCs as a highly biocompatible
nanoantibiotic for bone tissue engineering.
Results and discussion
In this work, we developed a novel wet-chemical synthetic
approach to obtain tiny and homogeneous ZnO NCs. The used
approach involves a fast, highly-reproducible and efficient
microwave-assisted synthesis method,26 hydrolysing the zinc
acetate dehydrate precursor in a polar solvent (methanol) in the
presence of potassium hydroxide. The microwave-assisted sol-
vothermal synthesis shows various advantages with respect to
conventional synthetic procedures. In fact, due to the rapid and
homogeneous heating it is possible to guarantee very fast
kinetic rates and short reaction times, low energy consumption
and simultaneous nucleation of nanocrystals that lead to the
obtaining of a uniform and reproducible dimensional range.27
Thanks to this process, highly-dispersed, round-shaped
nanocrystals as an extremely-stable colloidal solution inRSC Adv., 2019, 9, 11312–11321 | 11313
RSC Advances Paperethanol and water were nally obtained. A portion of them were
also chemically modied by anchoring amino-propyl groups to
the ZnO surface, as previously reported.10,28,29 The produced
nanomaterials were then characterized as described below.
Morphological and structural characterization of the ZnO NCs
X-ray diffraction (XRD) was performed in order to obtain
information about phase identication, along with phase
quantication, percentage of crystallinity, crystallite size and
unit cell size. Fig. 1a and b show the XRD patterns of the pris-
tine ZnO NCs and ZnO–NH2 NCs. A comparison of the patterns
with the data bank (JCPDS 36-1451) conrmed the crystalline
structure of the particles. In particular, the peaks at 31.9, 34.4,
36.4, 47.6, 56.7 can be indexed to the (100), (002), (101), (102)
and (110) planes, respectively. These correspond to the Miller
indexes of hexagonal wurtzite structured ZnO, according to the
literature30,31 and are comparable with the standard reference
pattern of ZnO. It is also clear that the chemical functionaliza-
tion did not alter the crystalline structure of ZnO. By using the
Debye–Scherrer formula and considering the dominant peaks,
it was possible to estimate the dimension of the crystallites, as
around 15 nm for both pristine and functionalized ZnO NCs.
Transmission electron microscopy (TEM) studies conrmed
these results and allowed additional information to be obtained
about the particle morphology and size (Fig. 1c and d), in both
cases showing a similar polygonal shape, typical of ZnO NCs.
The stability behaviour of the ZnO NCs showed highlyFig. 1 Structural andmorphological characterization: XRD patterns for (a
NH2 NCs.
11314 | RSC Adv., 2019, 9, 11312–11321monodispersed particles sizes for both pristine and amine-
functionalized ZnO NCs in both ethanol and water media, as
supported by the dynamic light scattering measurements
shown in Fig. S1 in the ESI.† The Fourier-transform infrared
(FTIR) spectra of both the ZnO and ZnO–NH2 NCs show some
common features between the two different samples, but in the
case of the ZnO–NH2 NCs, the presence of typical vibration
modes associated with the functional groups present in the 3-
aminopropyltrimethoxysilane molecule (APTMS) conrms the
successful functionalization of the ZnO surface (Fig. S2 in the
ESI†).
Biocompatibility studies
The biocompatible or cytotoxic behaviours of both pristine and
functionalized ZnO NCs at different concentrations were
monitored in living pre-osteoblast cells from mouse calvaria.
Both lactate dehydrogenase (LDH) production and the mito-
chondrial activity (MTT) were recorded aer 3 days of cell
incubation with the nanocrystals with and without functional-
ization and at different concentrations, to give a complete
picture of the cytotoxicity and the cell proliferation behaviour.
LDH is an enzyme released by cells in case of cell membrane
rupture, thus indicating a cytotoxic effect. Interestingly, the
LDH tests reported in Fig. 2a and c for both pristine and
functionalized ZnO NCs, respectively, evidenced no cytotoxic
effect in both cases up to a concentration of 50 mg mL1 of NCs.
Actually, no signicant differences were registered in) ZnO and (b) ZnO–NH2 NCs; TEMmicrographs of (c) ZnO and (d) ZnO–
This journal is © The Royal Society of Chemistry 2019
Fig. 2 In vitro biocompatibility assays: cytotoxicity by LDH released into the medium after 3 days of incubation with different concentrations of
the (a) ZnO and (c) ZnO–NH2 NCs. Proliferation results in terms of mitochondrial activity (MTT) after 3 days of incubation and with different
concentrations of (b) ZnO and (d) ZnO–NH2 NCs (p < 0.05, significant differences compared to the control are denoted by an asterisk (*)).
Paper RSC Advancescomparison with the control test. In contrast, a concentration of
100 mg mL1 for both pristine ZnO NCs and ZnO–NH2 NCs
exhibited a cytotoxic effect on pre-osteoblast cells, displaying
a double quantity of LDH produced with respect to the control.
The MTT proliferation test is based on the ability of mito-
chondrial enzymes to reduce the MTT molecule to formazan.
This measurement is commonly related to the cell viability and
proliferation, as previously reported in the literature.32 Accord-
ing to Fig. 2b and d, both pristine and functionalized ZnO NCs
show adequate cell proliferation up to a certain concentration:
in general, a decrease in mitochondrial activity occurred upon
an increase in the concentration of NCs with respect to the
control without nanocrystals. The proliferation ranges from 90
to 70% up to a concentration of 25 mg mL1 (compared to the
control), then a slight decrease occurs for 50 mg mL1 (z60%)
both for the pristine and functionalized NCs. Regarding the
highest concentration of 100 mg mL1, there is a signicant
reduction of the proliferation down to 27% for ZnO NCs and
43% for ZnO–NH2 NCs compared to the control. These results
are in line with the LDH test. Therefore, both the LDH and MTT
assays highlighted the great biocompatibility of ZnO and ZnO–
NH2 up to a concentration of 50 mg mL
1. On the other hand,
a concentration of 100 mg mL1 showed cytotoxic activity and
inhibited cell proliferation. This cytotoxic effect is generally
reported in the literature10,26 as an intracellular release of cyto-
toxic Zn2+ cations due to ZnO dissolution, or as a consequence
of oxidative stress by ROS, due to the presence of intracellular
ZnO.33This journal is © The Royal Society of Chemistry 2019In order to gain further information on the biocompatibility
behaviour, another assay was performed. The cells were
cultured up to 70% conuence and then treated with the
nanocrystals (at different concentrations and with or without
functionalization). This procedure was necessary to simulate
the interaction between pre-formed bone tissue and antibacte-
rial agents, in order to analyse how they may affect the viability
of the tissue. In this case, the proliferation via MTT was
measured aer 24 h of incubation (Fig. 3) and the cell
morphology was studied under a uorescence microscope aer
4 days of incubation (Fig. 4). The values of the MTT tests are of
the same order of the control up to a concentration of 50 mg
mL1 for pristine ZnO NCs. Actually, the mitochondrial activity
is around 100% or higher compared to the control, with a peak
in the mitochondrial activity for a concentration of 25 mg mL1,
where the proliferation increased up to 130%. Unfortunately,
a signicant decrease occurred in relation to the highest
concentration (100 mg mL1), where the mitochondrial activity
dropped down to 41%. These results are indeed comparable to
what is reported in Fig. 2, again showing the concentration-
dependent biocompatibility of the ZnO NCs.
The results of ZnO–NH2 are similar, with just a few differ-
ences. The best proliferation value was obtained for a concen-
tration of 25 mg mL1, but the peak is less pronounced.
Interestingly, a concentration of 100 mg mL1 did not show
signicant differences and the mitochondrial activity was still
close to that of the control. This result highlights the rst
difference between pristine and functionalized ZnO NCs.RSC Adv., 2019, 9, 11312–11321 | 11315
Fig. 3 Proliferation results in terms of MTT of MC3T3-E1 (at 70%
confluence) and incubated for 1 day with different concentrations of
(a) ZnO and (b) ZnO–NH2 NCs (p < 0.05, significant differences
compared to the control denoted by an asterisk (*)).
Fig. 4 Confocal microscopy images of pre-osteoblasts cultured up to
70% confluence after incubation for 4 days with ZnO and ZnO–NH2
NCs at different concentrations. All confocal images were obtained
under the same conditions and show the Z projection of different
images taken at different depths.
RSC Advances PaperConfocal microscope images gave further information and
allowed the investigation of the cell morphology aer ZnO NC
incubation. Actin was stained with Atto565-conjugated phalloi-
din (red) and nuclei were stained with DAPI (blue). Fig. 4 shows
the typical well-spread morphology of the osteoblasts aer
incubation with ZnO NCs at 25 mg mL1. In addition, further
images at the other concentrations are reported in Fig. S3 and S4
in the ESI.† Note that there is a slight increase in the number of
cells aer incubation with the nanoparticles at 25 mg mL1,
which was conrmed by an increase in the cellular thickness
from 73 10 mm for the control to 123 15 mm in the presence of
the ZnO NCs. On the contrary, at a higher concentration of
pristine ZnO NCs (100 mg mL1), the cells exhibited a spherical
morphology, non-dened actin laments and reduced conu-
ence, indicating a clear cytotoxic effect at this concentration.
These results conrm the previous results, evidencing the good
biocompatibility of the ZnO NCs up to 50 mg mL1.7
Regarding the functionalized ZnO–NH2 NCs, this cytotoxic
effect was less noticeable, because the cells in contact with 100 mg
mL1 show a well-spread morphology and still have uorescent
actin laments, but the grade of conuence was inferior compared
to that of the control cells. ZnO–NH2 was again conrmed to be11316 | RSC Adv., 2019, 9, 11312–11321more biocompatible, especially for the highest sample concentra-
tion of 100 mg mL1, under these experimental conditions.Differentiation assay: ALP
Differentiation is a process by which unspecialized cells, pre-
osteoblasts, become specialized cells with the function to
restore bone. For this purpose, the activity of ALP (alkaline
phosphatase), a marker enzyme for determining osteoblast
phenotype was monitored. In particular, the ALP activity of both
kinds of ZnO NCs was determined aer 10 days of incubation in
pre-osteoblast cells. In Fig. 5a, it is possible to observe the
progressive decrease in the ALP activity upon an increase in the
concentration of the ZnO NCs, and even in this case the lowest
value was for 100 mg mL1. Regarding the total protein content
(top of Fig. S5 in the ESI†), the trend is very similar to that of the
ALP activity. No signicant differences are observed up to
a concentration of 10 mg mL1, while there is a drop from 25 mg
mL1 to higher concentration values. On the other hand, the
ZnO–NH2 NCs showed different behaviour. As can be observed
in Fig. 5b, there are no signicant differences compared to the
control in terms of the ALP activity, evidencing that there is no
apparent inhibition at the lower concentrations of nano-
particles (below 100 mg mL1). At the highest concentration of
100 mg mL1, around 20% decrease in the ALP activity was ob-
tained. A similar trend was observed for the total protein
content, as shown in the part of Fig. S5 in the ESI.†
The cell morphology under a bright eld optical microscope
was also recorded at every concentration, both for the pristine
and functionalized incubated NCs (see Fig. S6 and S7 in the
ESI†). MC3T3-E1 cells exhibit a well spread morphology, with
a high degree of conuence, up to a concentration of 50 mg
mL1 for pristine ZnO NCs. As observed above, the cells treated
with 100 mg mL1 of ZnO NCs present a spherical morphology,
indicating cell sufferance and death, with a minor grade of
conuence.This journal is © The Royal Society of Chemistry 2019
Fig. 5 Differentiation assays in terms of ALP after 10 days of incuba-
tion with the (a) ZnO and (b) ZnO–NH2 NCs at different concentrations
(p < 0.05, significant differences compared to the control denoted by
an asterisk (*)).
Paper RSC AdvancesRegarding the cells treated with ZnO–NH2 NCs for ten days at
different concentrations, in all cases a well-spreadmorphology of
MC3T3-E1 cells was observed, including the highest concentra-
tion of 100 mg mL1 for ZnO–NH2 NPs. We observed a slightly
lower conuence for the most concentrated sample with respect
to the others. However, these optical microscope images
conrmed the results of the ALP activity and total protein
content, showing the prominent biocompatible and osteoin-
ductive role, even at high concentrations, of the ZnO–NH2 NCs.Antimicrobial activity
The antimicrobial activity of different NCs was determined
against Gram positive (S. aureus) and Gram negative (E. coli)
bacteria at the planktonic stage, aer 24 h of incubation at
different concentrations. Fig. 6 summarizes these results in
terms of the logarithmic scale of CFU (colony-forming unit)
quantication. The obtained results show a remarkable anti-
microbial effect of both pristine ZnO and functionalized ZnO–
NH2 NCs against the two types of bacteria. However, there were
notable differences between both strains. Regarding the anti-
microbial activity against E. coli, it is very interesting to notice
that in particular, there is no effect of NC concentration, each
one showing a 100% reduction in bacteria viability. The same
behaviour was observed for both pristine and functionalizedThis journal is © The Royal Society of Chemistry 2019nanocrystals. On the other hand, the activity against S. aureus
was slightly different.
A peak in the antimicrobial activity was obtained for
a concentration of 25 mg mL1 for both the ZnO and ZnO–NH2
NCs, showing a reduction in the viability of around 99.98 and
99.99% (less than 100 CFU mL1), respectively. In contrast, the
antimicrobial activity was reduced at a higher concentration, in
particular for a concentration of 50 mg mL1 of the ZnO–NH2
NCs, resulting in only 99.85% of bacteria inactivation (in this
case the concentration was higher at 102 CFU mL1, which could
be considered not effective). This performance could be
explained by the aggregation of the nanocrystals when dispersed
in PBS, as previously observed by some of our group.31 In fact, by
increasing the concentration, there is greater probability of
forming huge aggregates, which means a lower surface area to
volume ratio, and thus reduced contact with the S. aureus pop-
ulation. This behaviour was not detected with E. coli probably
because of the different shape and resistance. In fact, E. coli
exhibits an elongated shape, while S. aureus a round shape, thus
aggregated NCs have a major probability of coming into contact
with E. coli. In addition, S. aureus is a more resistant and path-
ogenic bacteria compared to E. coli. For further information,
Table S1† summarizes the reduction in the bacteria viability.Experimental
ZnO synthesis and functionalization
ZnO NCs were synthesized through a novel microwave-assisted
synthesis approach using zinc acetate dihydrate (0.1 M) and
potassium hydroxide (0.2 M) precursors (both from Sigma-
Aldrich) dispersed in methanol as a solvent. The solution con-
taining the zinc precursor was prepared and stirred directly in
the reactor vessel. In order to initiate zinc oxide nucleation, 0.48
mL of double-distilled water were added and then it was mixed
together with the KOH solution in the reactor vessel. The
resulting solution was put into a microwave oven for 30 minutes
under controlled pressure at a temperature of 60 C. Aer this
time, the colloidal dispersion was collected and centrifuged for
10 minutes at 5000 rpm (3500 rcf), in order to separate the
methanol and reaction residuals from the newly-formed ZnO
NCs. The surfactant was then removed and the precipitate was
dispersed and washed in 15 mL of ethanol twice. The as-
obtained ZnO NCs pellet was suspended in fresh ethanol to
give the nal colloidal suspension.
The functionalization step of ZnO NCs with amino groups
(NH2) was carried out by combining the nanocrystals with 3-
aminopropyltrimethoxysilane, (APTMS, 97%, Sigma), as already
reported in ref. 10. In more detail, 100 mg (1.23 mmol) of ZnO
NCs, dispersed in ethanol, were heated to 80 C in a 100 mL
round-bottomed ask under continuous stirring and nitrogen
gas ow. 15 minutes later, 21.4 mL of APTMS (0.123 mmol,
22.05 mg, corresponding to 10 mol% of the total ZnO amount)
was added to the solution. The obtained mixture was reuxed
under a nitrogen gas ow for 6 h and successively washed twice
by separating the NCs under centrifugation (10 min, 10 000
rpm) to remove the unbound APTMS molecules.RSC Adv., 2019, 9, 11312–11321 | 11317
Fig. 6 Logarithmic scale of CFU per mL of E. coli and S. aureus at the planktonic stage incubated for 24 h in the presence of different
concentrations of ZnO and ZnO–NH2 NCs (p < 0.05, significant differences compared to the control denoted by an asterisk (*) in absolute value).
RSC Advances PaperCharacterization
The ZnO NCs obtained from the microwave-assisted synthesis
were characterized by comparing data from different batches in
order to conrm the repeatability of the synthesis. In particular,
the samples were analyzed by XRD in order to investigate the
crystalline structure. A Panalytical X'Pert diffractometer in
conguration 0–2q Bragg–Brentano was employed, equipped
with a Cu-Ka radiation source (l ¼ 1.54 A˚, 40 kV to 30 mA). The
samples were prepared by depositing the colloidal solution
drop by drop on a silicon wafer, in order to have a sufficiently
thick layer of nanocrystals. The XRD analysis was carried out
with a step size of 0.02 (2q), in the 2q range of 20–70 with an
acquisition time of 100 s.
Transmission electron microscopy (TEM) characterization
was also used to assess the morphology, size, shape and crys-
tallinity of the nanocrystals. The samples were diluted in ultra-
pure ethanol (99%) up to a concentration of 200 mg mL1 and
then one drop was deposited on a copper grid with carbonmesh
for high-resolution (HR-TEM) analysis. The measurements were
performed with JEM 2100HT (JEOL) multipurpose analytical
HR-TEM, with an accelerating voltage of 200 kV and point
resolution of 0.25 nm. HR-TEM images were acquired using
a charge coupled device (CCD) camera.11318 | RSC Adv., 2019, 9, 11312–11321Cell culture conditions
MC3T3-E1, pre-osteoblasts cells frommouse calvaria were used.
Cells were grown in complete Dulbecco's modied Eagle's
medium (a-DMEM, Sigma Chemical Company, St. Louis, MO,
USA) supplemented with 2 mM L-glutamine (BioWhittaker), 100
mg mL1 penicillin (BioWhittaker), 100 g mL1 streptomycin
(BioWhittaker) and 10% fetal bovine serum (FBS, Gibco) at
37 C under atmosphere conditions of 95% humidity and 5%
CO2. The medium was changed every day until conuence was
reached z90% in a P75 ask. Then, the cultures were trypsi-
nized with a solution of 0.05% (w/v) trypsin and 0.02% (w/v)
EDTA in sterile phosphate buffered saline (Sigma-Aldrich) and
counted with a Neubauer hemocytometer. Cells were then
centrifuged at 310 g for 10 min and suspended in fresh medium
at a density of 2  104 cells per mL.
In cellular assays, the behavior of both the pristine ZnO and
ZnO–NH2 NCs was studied at the following concentrations: 5,
10, 25, 50, and 100 mg mL1. The desired amount of NCs was
taken away from the stock solutions in ethanol, centrifuged to
pellet the NCs, discarding the ethanol, and then the NCs were
dispersed in the nal volume of cell culture medium. ZnO-free
suspensions were used as a control. In addition, two different
experiments were performed. In the rst, cells and the ZnOThis journal is © The Royal Society of Chemistry 2019
Paper RSC Advancesnanostructures were put into contact at the same time, to
analyze the situation when stem cells and antimicrobial agents
simultaneously meet. In the second assay, cells were cultured
up to 70% conuence, and then the nanocrystals were added.
This procedure simulates the interaction between pre-formed
bone tissue and an antibacterial agent, in order to analyse
how they may affect the viability of the tissue.Cytotoxicity test – LDH
LDH activity was determined in culture medium in contact with
nanocrystals aer 3 days of incubation. The activity of LDH
released by the MC3T3-E1 cells is directly related to the rupture
of the plasmatic membrane (cell death) that, when broken,
releases all organelles and enzymes present in the cytoplasm.
For this purpose, 0.750 mL of cell suspension with a concen-
tration of 1.33  104 cells per mL and 0.250 mL of NC suspen-
sions with the desired concentration were added in each plate.
Aer adding NCs in the cell suspensions, the well plates were
le to incubate under CO2 (5%) atmosphere at 37 C for 3 days.
Measurements were performed using a commercial kit (Spin-
react) at an absorbance at 340 nm with a UV-visible spectro-
photometer. Two replicates were done for each concentration.Mitochondrial activity – MTT
To evaluate the cell mitochondrial activity of living cells on the
different plates as well as their surroundings aer 1 and 3 days
of incubation, the MTT method was employed. This method is
based on the reduction of 3-(4,5-dimethylazol-2-yl)-2,5-
diphenyltetrazolium (yellow) to blue formazan. This measure-
ment was used in terms of cell proliferation. For this purpose,
0.750 mL of MC3T3-E1 cells in a concentration of 104 cells
per mL in complete medium were cultured in 24-well plates in
the presence of 0.250 mL of ZnO or ZnO–NH2 NC suspension at
different concentrations and incubated in a 5% CO2 atmo-
sphere at 37 C for 3 days. This test was replicated for pre-
formed bone tissue, where NCs were incubated for 1 day with
cells at 70% conuence. Aer this time, the culturemediumwas
substituted with 1 mL of a-MEM and 125 mL of MTT solution
(5 mg mL1 in PBS 1) was added. Samples were incubated for
4 h at 37 C and 5% CO2 in the dark. Then, the medium was
removed and 500 mL of a 0.4 M HCl–isopropanol solution was
added. At the end, the absorbance at 570 nm was measured.
Two replicates were done for each concentration.Cell morphology studies
The morphology of pre-osteoblast cells MC3T3-E1 was studied
using an AMG EVOS  LED uorescence microscope. For this
purpose, cells were cultured up to 70% conuence, and then the
medium was removed. Aerwards, 0.750 mL of complete a-
MEM and 0.250 mL of NC suspensions with the desired
concentrations were added to each plate. Samples were incu-
bated for 4 days. Aer this time, adherent cells were xed with
paraformaldehyde (4% in PBS) for 30 minutes. Then, Atto 565-
conjugated phalloidin and DAPI were added to each plate to
stain the cell actin in red and cell nuclei in blue, respectively.This journal is © The Royal Society of Chemistry 2019Differentiation assay: alkaline phosphatase activity – ALP
To evaluate the differentiation of MC3T3-E1, ALP measure-
ments were employed. ALP is an enzyme present in most
organisms, found in high quantities in the bone, liver, placenta,
intestine and kidney. ALP activity of the cells growing in contact
with ZnO nanostructures was utilized as a marker of cellular
differentiation in the evaluation of the phenotype expression of
osteoblasts.
For this purpose, MTC3T3-E1 pre-osteoblastic cells (104 cells
per mL) were cultured directly in a 24-well plate and incubated
for 10 days in contact with ZnO and ZnO–NH2 under standard
culture conditions (37 C, 5% CO2) using a-MEM completed
medium supplemented with beta-glycerolphosphate (50 mg
mL1) and L-ascorbic acid (10 mM). In particular, 0.750 mL of
cell suspensions with a concentration of 1.33  104 cells per mL
and 0.250 mL of NCs suspensions with the desired concentra-
tion were added to each plate. Two replicates were done for each
samples in two independent assays (n ¼ 4).
Aer incubation for 10 days, the medium was taken off and
every well plate was washed twice with PBS (pH 7.4). Succes-
sively, samples were frozen and before the measurement they
were frozen and unfrozen 3 times in order to break the cell
membrane and release ALP. ALP was measured using a Spin-
react kit.CFU counting method
To examine the bactericidal effect of ZnO NCs on bacteria, at the
planktonic stage, direct incubation with bacteria solution in
PBS was carried out. Both E. coli 25922 and S. aureus ATCC29213
(methicillin-sensitive) were used. In this case, concentrations of
5, 10, 25, 50, and 100 mg mL1 were used in order to determine
their effectivity. For this purposes 0.750 mL of bacteria
suspensions in PBS with a concentration of 1.33  106 bacteria
per mL and 0.250 mL of NC suspensions with the desired
concentration were added to each well of a 24-well plate. Then,
NC and bacteria suspensions were incubated for 24 h under
orbital stirring at 37 C. Two different experiments were per-
formed in triplicate. The quantication of living bacteria was
determined by CFUs in agar. In order to be more accurate, the
original solution and different dilutions (1/10, 1/100 and 1/1000
dilutions) were used.34 Thus, 20 mL of such solutions was seeded
onto trypsin soy agar (TSA), incubated at 37 C overnight and
subsequently the number of CFUs was counted. Positive
controls containing bacteria were also used and the experi-
ments were performed in triplicate.Statistical analysis
Data are expressed as average/mean standard deviation in the
two experiments. The soware Statistical Package for the Social
Sciences (SPSS) version 11.5 was used to perform statistical
analysis. The variance analysis (ANOVA) was utilized for statis-
tical comparisons. Scheffe´’s test was used for the post hoc
evaluation of the differences among the groups. In all statistical
evaluations, p < 0.05 was considered as statistically signicant.RSC Adv., 2019, 9, 11312–11321 | 11319
RSC Advances PaperConclusions
In this work, uniform and highly crystalline ZnO nanoparticles
were synthesized using an innovative microwave-assisted sol-
vothermal synthesis to obtain nanocrystals of 20 nm in diam-
eter. The results highlighted that ZnO NCs show great
biocompatibility towards pre-osteoblast cells and promising
antimicrobial activity against E. coli and S. aureus. Moreover, the
biocompatibility and antibacterial assays performed on the
functionalized ZnO–NH2 NCs also demonstrated that ne
control over the ZnO chemical surface by amine-
functionalization further improved both the biocompatibility
in terms of cell differentiation and proliferation and their
antimicrobial capability. These ndings open up new horizons
in the use of ZnO NCs as a highly biocompatible nanoantibiotic
for bone tissue engineering.
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